Current location:


Choose your location:

SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong


April 14, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in Hong Kong, China.


SINOVAC continuously carried out the development of COVID-19 vaccines targeting the Gamma and Delta strains during 2021. When the Omicron variant was first reported to WHO on November 24, SINOVAC quickly obtained the strain by early December, actively promoted development and preclinical research that has demonstrated the vaccine is safe and effective in animals.


In February 2022, SINOVAC began submitting clinical applications for its Omicron-specific COVID-19 vaccine to countries and regions globally. The clinical approval in Hong Kong is the first for the SINOVAC Omicron strain inactivated vaccine. SINOVAC will continue its extensive cooperation with global partners to promote research on its vaccine based on the original COVID-19 strain against emerging variants, as well as clinical research on sequential immunization of new variant strain vaccines, to evaluate their safety and effectiveness.



Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.


SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.


The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.


SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.


SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.


For more information, please see the Company’s website at






Sinovac Biotech Ltd.


PR Team